Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.69 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306415 | 1.00 | P2RX7 (0.69) | P2RX7PPARGPPARDPPARAPDE10A | |
| SCHEMBL17690515 | 0.91 | P2RX7 (0.57) | P2RX7PPARGPPARDPPARAPTGER4 | |
| SCHEMBL306167 | 0.90 | P2RX7 (0.61) | P2RX7PPARGPPARDPPARAPDE10A | |
| SCHEMBL306166 | 0.90 | P2RX7 (0.61) | P2RX7PPARGPPARDPPARAPDE10A | |
| SCHEMBL308127 | 0.89 | P2RX7 (0.55) | P2RX7PPARGPPARDPPARAPDE10A | |
| SCHEMBL308126 | 0.89 | P2RX7 (0.55) | P2RX7PPARGPPARDPPARAPDE10A | |
| SCHEMBL307031 | 0.87 | P2RX7 (0.52) | P2RX7PDE10AS1PR3 | |
| SCHEMBL17685471 | 0.85 | P2RX7 (0.66) | P2RX7PPARGPPARDPPARAPDE10A | |
| SCHEMBL306445 | 0.85 | P2RX7 (0.49) | P2RX7ELANE | |
| SCHEMBL8127026 | 0.84 | P2RX7 (0.51) | P2RX7PPARGPPARDPPARAS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124562-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8093265-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885PPARG 414/4885PPARD 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.